Shao-Lee Lin, as the first chief scientific officer at Horizon Therapeutics, was the head of research and development, changing the trajectory of the company. Within her first year, she strategically assembled a diverse team and delivered dramatic results in the company’s phase three trial for the first potential treatment of thyroid eye disease. She continued to foster an environment that encouraged taking calculated risks to address challenges and diseases that many would not, and she valued “fast failure” as part of that breakthrough discovery process.

As corporate officer and vice president at AbbVie, Lin led the expansion of the drug development pipeline across neuroscience, immunology, virology, and general medicine. In under three years, her teams rapidly brought multiple new medicines through from proof of concept to submission for approval in the US and internationally.

Lin earned her bachelor’s in chemical engineering and biochemistry from Rice University and her received MD and PhD at the Johns Hopkins University School of Medicine. Lin has served as a clinical scholar at the Rockefeller University and as adjunct faculty as Cornell, UCLA, Stanford, and Northwestern medical schools.

On the College’s Board of Trustees, Lin will serve on the Post-Graduate Outcomes and Student Success committees.    

Martino Moore ’99 serves as an Executive Director on the Institutional Sales trading desk at Morgan Stanley. Moore joined Morgan Stanley in June 1999 and is the primary sales trader for more than 100 institutional investors —Peter Dipietro ’20